Ovarian Cancer Drug Sensitivity Study
Author Information
Author(s): A.P. Simmonds, E.C. McDonald
Primary Institution: Royal Maternity Hospital and Royal Infirmary, Glasgow
Hypothesis
Can drug sensitivity profiles of ovarian carcinoma cells be correlated with clinical outcomes?
Conclusion
The study found that in vitro sensitivity to cis-platinum and adriamycin was related to a good clinical response in untreated patients.
Supporting Evidence
- 60% of untreated samples were sensitive to cis-platinum.
- 87% of untreated samples were sensitive to adriamycin.
- 81% of cases sensitive to adriamycin were also sensitive to cis-platinum.
- 80% of samples from treated patients were resistant to drugs already received.
Takeaway
Researchers grew ovarian cancer cells in the lab to see how they reacted to different drugs, finding that some patients' tumors were sensitive to treatment.
Methodology
Ovarian tumor samples were cultured using a clonogenic assay to assess drug sensitivity to cis-platinum, adriamycin, and phosphoramide mustard.
Limitations
The study had a small sample size for some drug tests and low plating efficiencies affected the number of evaluable samples.
Participant Demographics
Samples were collected from 106 patients with ovarian cancer, including various tumor types and stages.
Want to read the original?
Access the complete publication on the publisher's website